Calcium folinate is indicated:
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
Calcium folinate is indicated
• To diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children. In cytotoxic therapy, this procedure is commonly known as “Calcium Folinate Rescue”;
• In combination with 5-fluorouracil in cytotoxic therapy.
For adult patients with type 2 diabetes mellitus:
Sitavia-MET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination
of sitagliptin and metformin.
Sitavia-MET is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a
sulphonylurea.
Sitavia-MET is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled
on their maximal tolerated dose of metformin and a PPARγ agonist.
Sitavia-MET is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and
exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide
adequate glycaemic control.
Antepartum
• Induction of labour for medical reasons, e.g. in cases of Rh problems, post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia)
• Stimulation of labour in hypotonic uterine inertia
• Early stages of pregnancy as adjunctive therapy for the management of incomplete, inevitable, or missed abortion.
Postpartum
• During caesarean section, but following delivery of the child
• Prevention and treatment of postpartum uterine atony and haemorrhage
Casgevy is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
- Casgevy is indicated for the treatment of transfusion-dependent β-thalassemia (TDT) in patients 12 years and older.
Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Acute coronary syndrome:
Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).
